Human medicines European public assessment report (EPAR): Insulin aspart Sanofi, insulin aspart, Date of authorisation: 25/06/2020, Revision: 7, Status: Authorised

Agenda - Webinar on the use of platform technologies in the non-clinical and clinical domains

LinkedIn Live: How EMA supports innovation in medicine development, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 February 2026, 14:30 (CET) to 25 February 2026, 15:00 (CET)

Medicines during pregnancy and breastfeeding

Human medicines European public assessment report (EPAR): Azarga, brinzolamide,timolol, Date of authorisation: 25/11/2008, Revision: 19, Status: Authorised

Drug Shortages Global Regulatory Working Group: Group statement published on behalf of the Working Group by EMA

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 57, Status: Authorised

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Date of authorisation: 26/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop), clopidogrel, Date of authorisation: 15/07/2008, Revision: 33, Status: Authorised